ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder

Pharmacogenomics Journal

Volumn 13, Issue 4, 2013, Pages 349-353

  De Klerk, O L ^a,b   Nolte, I M ^a   Bet, P M ^c   Bosker, F J ^a   Snieder, H ^a   Den Boer, J A ^a   Bruggeman, R ^a   Hoogendijk, W J ^d   Penninx, B W ^a,c,e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GGZ Drenthe   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ABCB1; Adverse drug reactions; Major depressive disorder; P glycoprotein; Single nucleotide polymorphism; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; MULTIDRUG RESISTANCE PROTEIN 1; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ABCB1 GENE; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DUTCH; ETHNIC GROUP; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RESTLESSNESS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SWEATING; WEIGHT GAIN; XEROSTOMIA;

EID: 84881128550     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.16     Document Type: Article

References (39)

1. Chan GN, Bendayan R. Molecular and functional characterization of pglycoprotein in vitro. Methods Mol Biol 2011; 686: 313-336.
2. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005; 33: 165-174.
3. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380-387.
4. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003; 54: 840-846.
5. Weber CC, Kressmann S, Ott M, Fricker G, Muller WE. Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 2005; 38: 293-300.
6. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197-204.
7. Mihaljevic PA, Bozina N, Sagud M, Rojnic KM, Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1439-1444.
8. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 398-404.
9. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154-179.
10. Lin KM, Chiu YF, Tsai IJ, Chen CH, Shen WW, Liu SC et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 2011; 21: 163-170.
11. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy Jr GM. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010; 20: 467-475.
12. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203-209.
13. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67: 1110-1113.
14. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2: 191-196.
15. De Luca V, Mundo E, Trakalo J, Wong GW, Kennedy JL. Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenomics J 2003; 3: 297-299.
16. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STARD sample. PLoS One 2008; 3: e1872.
17. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121-140.
18. World Health Organization. ATC/DDD Index 2010; [update 27 October 2009; cited 5. December 2009]. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. Available from: http://www.whocc.no/atcddd, 2011.
19. Störmer E, von Moltke LL, Perloff MD, Greenblatt DJ. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol 2001; 41: 708-714.
20. Szabo D, Szabo Jr G, Ocsovszki I, Aszalos A, Molnar J. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 1999; 139: 115-119.
21. Wang JS, Zhu HJ, Gibson BB, Markowitz JS, Donovan JL, DeVane CL. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull 2008; 31: 231-234.
22. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-796.
23. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76: 22-76.
24. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100.
25. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W et al. Adverse reactions to antidepressants. Br J Psychiatry 2009; 195: 202-210.
26. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14: 1105-1118.
27. Qian W, Homma M, Itagaki F, Tachikawa H, Kawanishi Y, Mizukami K et al. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol Pharm Bull 2006; 29: 2446-2450.
28. Boomsma DI, Willemsen G, Sullivan PF, Heutink P, Meijer P, Sondervan D et al. Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. Eur J Hum Genet 2008; 16: 335-342.
29. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry 2009; 14: 359-375.
30. Marchini J, Howie B. Comparing algorithms for genotype imputation. Am J Hum Genet 2008; 83: 535-539.
31. Barak Y, Swartz M, Levy D, Weizman R. Age-related differences in the side effect profile of citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 545-548.
32. Sramek JJ, Cutler NR. The Impact of Gender on Antidepressants. Curr Top Behav Neurosci 2011; 8: 231-249.
33. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76: 449-462.
34. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
35. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002; 53: 79-91.
36. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011; 21: 152-161.
37. Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004; 5: 11-19.
38. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006; 26: 1601-1607.
39. Weiss J, Haefeli WE. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. Int Rev Cell Mol Biol 2010; 280: 219-279.